(Original title: Will the acquisition of Kunming Pharmaceutical Group fall below the acquisition price of China Resources Sanjiu?) Economic Observer reporter Zhang Xiaohui A merger and acquisition that is expected to be the largest in China’s pharmaceutical industry in 2022 is attracting the attention of the capital market. China Resources Pharmaceutical Holdings Co., Ltd. (hereinafter referred to as “China Resources Pharmaceutical”), which is well-known in the industry for mergers and acquisitions, intends to purchase Kunpharm Group Co., Ltd. (600422.SH, hereinafter referred to as “Kunpharm Group”) in cash. . The acquisition of China Resources Pharmaceutical was carried out through its listed…